US stock futures flat after Wall St drops on Trump tariffs, soft jobs data
Vericel (NASDAQ:VCEL) Corp’s stock has reached a new 52-week low, trading at $37.38. This marks a significant downturn for the company, which has seen its stock value decrease by 28.23% over the past year. Despite the decline, InvestingPro data shows the company maintains strong fundamentals with a current ratio of 5.01 and impressive gross margins of 72.54%. The biotechnology firm, known for its advanced cell therapies, is facing market challenges that have contributed to this decline. However, the company continues to show revenue growth of 14.8% over the last twelve months. Investors are closely monitoring the situation as the company navigates these difficulties, with analyst price targets suggesting potential upside of 47% from current levels. For deeper insights into Vericel’s valuation and growth prospects, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Vericel Corporation reported its Q1 2025 earnings with a record total net revenue of $52.6 million, slightly below the forecast of $53.84 million. The company experienced a net loss of $11.2 million, translating to a loss of $0.23 per share, which was wider than the expected EPS forecast of -$0.1338. Despite this, Vericel has raised its full-year revenue growth guidance to 20-23% and expects Q2 revenue growth of 22-25%. Canaccord Genuity and Truist Securities both reiterated their Buy ratings on Vericel, with price targets set at $61.00 and $52.00, respectively. Analysts from these firms expressed confidence in the launch of the MACI Arthro technique, which has shown promising early results and is anticipated to enhance Vericel’s market position. BTIG also maintained its Buy rating with a price target of $51.00, noting Vericel’s lead in the cartilage repair market despite potential competition from OrthoCellix. The company plans to expand its sales force in the second half of the year to support growth, particularly in its MACI and burn treatment products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.